Canopy Growth
One of the original Canadian LPs. Formerly backed by Constellation Brands with US expansion through Acreage Holdings.
Analyst Coverage
Cannabis Investor News in-house rating · cin-analyst-v1.0
The model outputs a Neutral rating for Canopy Growth, scoring 53/100 at conviction 2 of 5. Four pillars feed the composite in fixed weights (35/25/25/15 for fundamentals, regulatory, market, and editorial), and no clause of the score is hidden from the reader. Regulatory carries this profile, printing 73 and setting the ceiling on the composite. The editorial pillar sits at 30, and is the main drag on the composite.
Pillar-level, the record reads as reported revenue growth of 9.6 percent year over year, an operating margin of -24.7 percent, gross margin of 28.0 percent, a market cap near 436 million, a filing cadence of 4 regulator events in the trailing 90 days, a jurisdictional posture reading of 80. Each of those data points tethers the Neutral conclusion to observable evidence. The scoring pipeline pulls only from primary regulatory filings, licensed fundamentals data, institutional pricing feeds, and CIN newsroom coverage, and each pillar exposes its own inputs. This lets Canopy Growth be lined up against the global cannabis coverage universe on identical inputs, with refresh cadence tied directly to primary-source ingest.
Filing cadence and jurisdictional posture remain the primary drivers, with regulatory contributing 73. A sustained lift in filing frequency across the trailing 90 days combined with zero enforcement events would tighten the Neutral conclusion.
- Headquarters
- 1 HERSHEY DRIVE, SMITH FALLS, A6, K7A0A8
- Phone
- 855-558-9333
- CEO
- Luc Mo***u
- CFO
- Thomas St***t
- SEC CIK
- 1737927
- Website
- Company website
- Market cap
- $435.5M
- Enterprise value
- $346.8M
- Price to book
- 0.84
- Price to sales
- 1.53
- EV / EBITDA
- 11014.10
- Revenue (TTM)
- $284.6M
- Gross profit (TTM)
- $79.5M
- EBITDA
- $-26.8M
- Operating margin
- -24.7%
- Profit margin
- -92.4%
- Rev growth YoY
- 9.6%
- Return on equity
- -44.7%
- Return on assets
- -3.9%
- EPS (TTM)
- $-0.62
- EPS est. current year
- $-0.47
- Wall St. target price
- $1.23
- Shares outstanding
- 422.2M
- Insider ownership
- 0.2%
- Institutional ownership
- 7.9%
- Beta
- 2.42
- Full-time employees
- 1,128
- GICS sector
- Healthcare
- GICS industry
- Drug Manufacturers - Specialty & Generic
- Annual report
- Latest 10-K
- Proxy statement
- Latest DEF 14A
- Filing portal
- SEDAR+
Help us keep coverage accurate. Submit an update for CIN editorial review.
Bullish and Bearish Analyst Opinions for Canopy Growth (CGC)
Cannabis Investor News aggregates analyst coverage, price targets, insider transactions, SEC filings, and financing activity for Canopy Growth (CGC), a cannabis-sector equity listed on NASDAQ in the Canadian LP category. Use this profile to compare bullish and bearish opinions, monitor Form 4 insider buys and sells, and review the latest quarterly results.
Analyst average price target $1.57.
CIN editorial stance: Risk Elevated. Headwinds: deep drawdown, net loss, insider selling. (3 bullish signals, 4 bearish signals.)
One of the original Canadian LPs. Formerly backed by Constellation Brands with US expansion through Acreage Holdings.
Latest price: $0.92 (-0.08%) on NASDAQ.
Historical Price Data
5-year weekly price history, intraday quotes, and 52-week range for CGC are maintained by Cannabis Investor News and refreshed throughout the trading day.